Table 1.
HIV-1 prevention studies in BLT mice and related studies in NHP
| PrEP | Route of viral exposure | Inhibitor | Transmission in the treated group | Transmission in the control group(s) | Refs |
|---|---|---|---|---|---|
| Topicala in BLT mice | Vaginal | Tenofovir | 1 of 8 | 3 of 4 | [39] |
| C52L | 0 of 7 | 10 of 12 | |||
| C5A | 0 of 8 | ||||
| PIE12-Trimer | 0 of 5 | ||||
| FTC-TDF | 1 of 9 | ||||
| TC247 | 3 of 7 | ||||
| NSC23766 | 4 of 4 | ||||
| 3 aptamer-siRNA chimeras | 2 of 4 | 4 of 4 + 4 of 4 | [45] | ||
| Systemic in BLT mice | Vaginal | FTC + TDF | 0 of 5 | 7 of 8 | [37] |
| Rectal | 0 of 9 | 12 of 19 | [38] | ||
| Intravenous | 1 of 8 | 6 of 6 | |||
| Topicalb in NHP | Vaginal (repeated exposures) | Tenofovir | 0 of 6 | 8 of 9 | [67] |
| FTC + tenofovir | 0 of 6 | 2 of 2 + 5 of 6 | |||
| Vaginal | TC247 | 1 of 6 | 21 of 23 | [68] | |
| Vaginal | C52Lc | 7 of 15 | 9 of 9 | [69] | |
| Systemic in NHP | Rectal (repeated exposures) | FTC + TDF | 2 of 6 (oral) 0 of 6 (subcutaneous) | 17 of 18 | [71] |
a
Inhibitors applied as solutions.
b
Inhibitors applied as gels.
c
The concentration was not fixed, but covered a range.